» Authors » Mark Rosen

Mark Rosen

Explore the profile of Mark Rosen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 81
Citations 1926
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta M, Choi H, Kemp S, Furth E, Pickup S, Clendenin C, et al.
bioRxiv . 2024 Dec; PMID: 39651222
Translational Relevance: Emerging small molecule KRAS inhibitors (KRASi) represent a new class of therapy for PDAC. Clinical tools that can provide biological insights beyond tumor size change are desirable for...
2.
Song I, Thompson E, Verma A, MacLean M, Duda J, Elahi A, et al.
Sci Rep . 2024 Jan; 14(1):53. PMID: 38167550
The objective of this study is to define CT imaging derived phenotypes for patients with hepatic steatosis, a common metabolic liver condition, and determine its association with patient data from...
3.
Fitzgerald T, Bishop-Jodoin M, Laurie F, Iandoli M, Smith K, Ulin K, et al.
Semin Radiat Oncol . 2023 Sep; 33(4):395-406. PMID: 37684069
Clinical trials have been the center of progress in modern medicine. In oncology, we are fortunate to have a structure in place through the National Clinical Trials Network (NCTN). The...
4.
Hall W, Li J, You Y, Gollub M, Grajo J, Rosen M, et al.
J Clin Oncol . 2023 Jul; 41(29):4643-4651. PMID: 37478389
Purpose: Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. Magnetic resonance tumor...
5.
Cao J, Pickup S, Rosen M, Zhou R
Mol Imaging Biol . 2023 May; 25(4):638-647. PMID: 37166575
Purpose: We demonstrated earlier in mouse models of pancreatic ductal adenocarcinoma (PDA) that K derived from dynamic contrast-enhanced (DCE) MRI detected microvascular effect induced by PEGPH20, a hyaluronidase which removes...
6.
Smith K, Ulin K, Knopp M, Kry S, Xiao Y, Rosen M, et al.
Front Oncol . 2023 Feb; 13:1015596. PMID: 36776318
Clinical trials have become the primary mechanism to validate process improvements in oncology clinical practice. Over the past two decades there have been considerable process improvements in the practice of...
7.
Mettikanont P, Kalluri A, Bittermann T, Phillips N, Loza B, Rosen M, et al.
J Clin Exp Hepatol . 2022 Jul; 12(4):1048-1056. PMID: 35814502
Background And Aims: The Liver Reporting and Data System (LI-RADS) is the standard classification of imaging findings of hepatic abnormalities for hepatocellular carcinoma (HCC) surveillance. We aimed to study the...
8.
Lederer K, Bettini E, Parvathaneni K, Painter M, Agarwal D, Lundgreen K, et al.
Cell . 2022 Feb; 185(6):1008-1024.e15. PMID: 35202565
Vaccine-mediated immunity often relies on the generation of protective antibodies and memory B cells, which commonly stem from germinal center (GC) reactions. An in-depth comparison of the GC responses elicited...
9.
Lederer K, Parvathaneni K, Painter M, Bettini E, Agarwal D, Lundgreen K, et al.
medRxiv . 2021 Sep; PMID: 34580676
Vaccine-mediated immunity often relies on the generation of protective antibodies and memory B cells, which commonly stem from germinal center (GC) reactions. An in-depth comparison of the GC responses elicited...
10.
Onishi N, Li W, Newitt D, Harnish R, Strand F, Nguyen A, et al.
Radiology . 2021 Aug; 301(2):295-308. PMID: 34427465
Background Suppression of background parenchymal enhancement (BPE) is commonly observed after neoadjuvant chemotherapy (NAC) at contrast-enhanced breast MRI. It was hypothesized that nonsuppressed BPE may be associated with inferior response...